It’s been just revealed that the FDA authorized booster shots of the Pfizer coronavirus vaccines for use on some groups on Wednesday. A lot of American workers became eligible.
It’s been just revealed by Yahoo News that the FDA authorized the boosters for people 65 and older and people 18 to 64 who are at a high risk of getting a severe case of covid 19.
It also approved the shots for people 18 to 64 who are at a higher risk of getting the disease while at work.
That could include healthcare workers, teachers, and grocery store employees, among other occupations, according to the same online publication.
“Today’s action demonstrates that science and the currently available data continue to guide the FDA’s decision-making for COVID-19 vaccines during this pandemic,” Acting FDA Commissioner Janet Woodcock said in a statement.
She added that the authorization was amended “to allow for a booster dose in certain populations such as health care workers, teachers, and daycare staff, grocery workers and those in homeless shelters or prisons, among others.”
Great news about ending the pandemic
The other day, we were revealing some pretty great news about things that could lead to the end of this terrible nightmare.
Yahoo News notes that upticks in new disease cases and hospitalizations in central southeastern states such as West Virginia and Kentucky are considered signs that the pandemic is on its way out and it’s shifting toward endemicity.
More and more people are gaining immunity to the coronavirus, and this is happening via either vaccination or infection.
In other news, USA Today just noted that Johnson & Johnson released new data, and this shows the fact that a booster dose of its vaccine given two months after the one-shot vaccine provides 94% protection against moderate-to-severe covid symptoms.
Also, a vaccine company has just revealed that Clover’s adjuvanted protein-based covid 19 vaccine candidate, SCB-2019 “achieved the primary efficacy endpoint and secondary efficacy endpoints in SPECTRA, a global pivotal Phase 2/3 clinical trial.”